Suggested treatments of CLL-associated AIHA
| Condition . | First-line treatments . | Second-line treatments . | References . |
|---|---|---|---|
| Untreated drug-related AIHA, untreated AIHA in early stage CLL | Steroids | RCD | 82,83 |
| Untreated AIHA in active CLL | Steroids + chlorambucil | RCD; R-CVP | 16,84,85 |
| Steroid-refractory, nonprogressive CLL | Rituximab; cyclosporin; splenectomy | RCD; R-CVP | 86,–88 |
| Multiply refractory AIHA, advanced or progressive CLL | Alemtuzumab | 89 |
| Condition . | First-line treatments . | Second-line treatments . | References . |
|---|---|---|---|
| Untreated drug-related AIHA, untreated AIHA in early stage CLL | Steroids | RCD | 82,83 |
| Untreated AIHA in active CLL | Steroids + chlorambucil | RCD; R-CVP | 16,84,85 |
| Steroid-refractory, nonprogressive CLL | Rituximab; cyclosporin; splenectomy | RCD; R-CVP | 86,–88 |
| Multiply refractory AIHA, advanced or progressive CLL | Alemtuzumab | 89 |
RCD indicates rituximab, cyclophosphamide, and dexamethasone; and R-CVP, rituximab, cyclophosphamide, vincristine, prednisone.